HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer-Reference-Cited by-同舟云学术

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer

Published:2023-11 Issue:11 Volume:36 Page:100299
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Modern Pathology

Author:

Shen Sherry,Ma Weining,Brown David,Da Cruz Paula Arnaud,Zhou Qin,Iaosonos Alexia,Tessier-Cloutier Basile,Ross Dara S.,Troso-Sandoval Tiffany,Reis-Filho Jorge S.,Abu-Rustum Nadeem,Zhang Yanming,Ellenson Lora H.,Weigelt Britta,Makker Vicky,Chui M. Herman^ORCID

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference37 articles.

1. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis;Moasser;Oncogene,2007

2. HER2-targeted therapies—a role beyond breast cancer;Oh;Nat Rev Clin Oncol,2020

3. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice;Buza;Mod Pathol,2013

4. HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes;Vermij;Cancers (Basel),2020

5. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas;Ross;Mod Pathol,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma;Human Pathology;2024-10

2. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

3. Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center;Cancers;2024-05-31

4. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2);Gynecologic Oncology;2024-03